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Abstract
Background: The cholinergic system and M1 receptor remain an important target for symptomatic treatment of
cognitive dysfunction. The selective M1 receptor partial agonist HTL0018318 is under development for the
symptomatic treatment of Dementia’s including Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB).
We investigated the safety, tolerability, pharmacokinetics and exploratory pharmacodynamics of multiple doses of
HTL0018318 in healthy younger adults and elderly subjects.
Methods: This randomised, double blind, placebo-controlled study was performed, investigating oral doses of
15–35 mg/day HTL0018318 or placebo in 7 cohorts of healthy younger adult (n = 36; 3 cohorts) and elderly (n = 50;
4 cohorts) subjects. Safety, tolerability and pharmacokinetic measurements were performed. Pharmacodynamics
were assessed using a battery of neurocognitive tasks and electrophysiological biomarkers of synaptic and cognitive
functions.
Results: HTL0018318 was generally well-tolerated in multiple doses up to 35 mg/day and were associated with
mild or moderate cholinergic adverse events. There were modest increases in blood pressure and pulse rate when
compared to placebo-treated subjects, with tendency for the blood pressure increase to attenuate with repeated
dosing. There were no clinically significant observations or changes in blood and urine laboratory measures of
safety or abnormalities in the ECGs and 24-h Holter assessments. HTL0018318 plasma exposure was dose-
proportional over the range 15–35 mg. Maximum plasma concentrations were achieved after 1–2 h. The apparent
terminal half-life of HTL0018318 was 16.1 h (± 4.61) in younger adult subjects and 14.3 h (± 2.78) in elderly subjects
at steady state. HTL0018318 over the 10 days of treatment had significant effects on tests of short-term (working)
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memory (n-back) and learning (Milner maze) with moderate to large effect sizes.
Conclusion: Multiple doses of HTL0018138 showed well-characterised pharmacokinetics and were safe and
generally well-tolerated in the dose range studied. Pro-cognitive effects on short-term memory and learning were
demonstrated across the dose range. These data provide encouraging data in support of the development of
HTL0018138 for cognitive dysfunction in AD and DLB.
Trial registration: Netherlands Trial Register identifier NTR5781. Registered on 22 March 2016.
Keywords: Muscarinic M1, M1 receptor, Cholinergic, Dementia, Safety, Pharmacokinetics, Cognition, Memory,
Healthy subjects
Background
Alzheimer’s disease (AD) and dementia with Lewy
bodies (DLB) are progressive neurodegenerative disor-
ders caused by complex pathophysiological processes
[1], leading to degeneration of the cholinergic neu-
rons in the basal forebrain and their projections to
the cortex and the hippocampus [2]. These choliner-
gic deficits play a key role in the underlying cognitive
impairments as well as some of the behavioural and
psychiatric symptoms including visual hallucinations
[3–7].
The complex pathology of AD and DLB has hampered
progress toward a curative treatment. Currently, the only
available treatment is symptomatic and consists mostly
of acetylcholinesterase inhibitors. Acetylcholinesterase
inhibitors (ChEIs) inhibit the breakdown of the neuro-
transmitter acetylcholine (ACh) and subsequently pro-
long the availability of ACh at the synapse. This leads to
activation of cholinergic muscarinic and nicotinic recep-
tors in the neocortex and hippocampus, which are in-
volved in cognitive function. Despite their ability to
improve cognition, ChEIs demonstrate only modest clin-
ical efficacy, likely due to ongoing neurodegeneration of
cholinergic neurons in dementia including AD and asso-
ciated decrease of ACh synthesis, and by a limited dos-
ing range of ChEIs because of side effects including
gastrointestinal side effects linked to indirect stimulation
of peripheral muscarinic M2 and M3 receptors [8–11].
Therefore, despite efforts to develop disease-modifying
treatments for AD, there is a need for improved symp-
tomatic treatments for AD and other dementia’s target-
ing not only cognitive symptoms but behavioural and
psychiatric symptoms. Optimization of the current treat-
ment options can be achieved by targeting post synaptic
muscarinic receptors, in particular M1 receptors in-
volved in cognitive function relative to other muscarinic
receptors (i.e. M2 and M3 receptors) associated with per-
ipheral side effects. Such selectivity might allow for
higher dosing, which could contribute to improved effi-
cacy for certain cognitive and/or behavioural symptoms.
Hence selective M1 receptor agonists may be promising
drugs for the treatment of cognitive, behavioural and
psychological symptoms in psychiatric and neurological
disorders (for a review, see Erskine et al. [12]).
The M1 muscarinic acetylcholine receptor (mAChR) is
the predominant mAChR in the central nervous system
and is highly expressed in the neocortex and hippocam-
pus [13, 14]. Pre-clinical studies suggest M1 agonists can
improve cognitive function including learning and mem-
ory [15–19]. Consistent with this evidence, muscarinic
receptor agonists including the M1/M4 agonist Xanome-
line and the M1 agonist GSK1034702 have shown prom-
ising early clinical effects [16, 20]. Xanomeline showed
improvement in global cognitive function (i.e. ADAS-
Cog), general clinical status (i.e. CIBIC+), and behav-
ioural symptoms such as delusions, hallucinations, and
agitation [20]. Similarly, the M1 agonist GSK1034702
was shown to improve episodic memory (international
shopping list task of the Cogstate battery) in a nicotine
abstinence model of cognitive dysfunction [16].
HTL0018318 (ethyl (3-endo)-3-(3-oxo-2,8-diazaspiro
[4.5] dec-8-yl)-8-azabicyclo [3.2.1] octane-8-carboxylate
hydrochloride), is a partial M1 mAChR agonist that has
been developed for the symptomatic treatment of cogni-
tive, behavioural and psychiatric symptoms in dementias
including AD and DLB. In pre-clinical studies,
HTL0018318 was found to be highly selective for the M1
receptor with an EC50 of approximately 100 nM and
with twofold selectivity for the M1 over M4 receptors
with no detectable functional agonist activity at human
M2 and M3 receptors. Pre-clinical studies have shown
HTL0018318 to reverse scopolamine-induced deficits in
passive avoidance learning in rats consistent with pro-
cognitive effects reported with other M1 agonists on
tests of learning and memory. The single ascending dose
(SAD) study with HTL0018318 has shown that single
doses of HTL0018318 up to 35mg were relatively well-
tolerated in healthy younger adult and elderly subjects
[21]. HTL0018318 was absorbed rapidly, peak plasma
concentration was typically reached 1–2 h post-dose and
the average elimination half-life was 12–16 h. Approxi-
mately 30% of the plasma unbound concentration en-
tered the cerebral spinal fluid. No consistent significant
effects on exploratory pharmacodynamic (PD) tests were
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observed. The SAD study was followed by the current
multiple-dose escalation study, in which we aimed to
investigate the safety, tolerability, pharmacokinetics




This was a double-blind, randomised, placebo-controlled,
parallel group study that consisted of 7 cohorts in
total: 3 cohorts of 12 younger adult healthy subjects
and 4 cohorts of 12 healthy elderly subjects. The
study design is shown in Fig. 1. The study was ap-
proved by the medical ethics review board of the
foundation Beoordeling Ethiek Biomedisch Onderzoek
(BEBO, Assen, The Netherlands) and conducted ac-
cording to the principles of the Declaration of
Helsinki and the ICH GCP guidelines [22].
Participants
Healthy younger adult subjects aged 18–55 years and
healthy elderly subjects aged 65 years and over, both
male and female, were enrolled to participate in the
study. Subjects were eligible if they were non-smokers,
in good health, with a resting systolic blood pressure be-
tween 90 and 140 mmHg, diastolic blood pressure be-
tween 50 and 90 mmHg and a heart rate between 45 and
100 bpm at screening. Main exclusion criteria were
current or past history of any physical, neurological or
psychiatric illness and currently on any medication in-
cluding antihypertensive drugs.
Investigational product
HTL0018318, in this study administered as the HCl salt,
was administered as a 100 ml oral solution. Water was
used as placebo. To mask the difference in taste be-
tween HTL0018318 and placebo, a peppermint strip
(Listerine) was administered 1 min before and after
the administration of HTL0018318. Subjects were not
asked if they could guess whether they received
HTL0018318 or placebo as the study was a parallel
group design with taste related unmasking having
minimal impact on unblinding.
Dose levels of 15 mg, 20 mg, 25 mg or placebo were
administered in a ratio 9:3 (active:placebo) once a day
for 10 consecutive days in both younger adult and eld-
erly subjects. The dose level of 35 mg was only studied
in a cohort with elderly subjects (8 subjects on
HTL0018318 and 4 subjects on placebo) and adminis-
tered to 3 subjects (including one replacement); how-
ever, lack of tolerability led to a titration regimen of 20
mg HTL0018318 once a day for 5 consecutive days
followed by 35mg HTL0018318 once a day for 10 con-
secutive days (7 subjects on HTL0018318 and 3 subjects
on placebo). Before implementing this new dosing regi-
men, the protocol was amended and approved.
HTL0018318 dosages were based on the tolerated dose
range of 1–35 mg in the SAD study.
Safety and tolerability assessments
The investigated safety end points were adverse events
(AEs) collected and recorded on the first dosing day,
continuing until the follow-up visit, safety laboratory
sampled at regular intervals, vital signs and electrocar-
diogram (ECG) conducted daily pre-dose and 1 h post-
dose, and with a higher frequency on the 1st, 5th and
10th dosing day, 24-h Holter registration performed at
the 1st and 10th dosing day and pulmonary function
tests (PFT). Cholinergically mediated AEs (i.e. AEs with
a (possible) relationship to increased cholinergic stimula-
tion) were identified. AEs in this category included;
hyperhidrosis, salivary hypersecretion, hypertension,
nausea, diarrhoea, vomiting, constipation, insomnia,
somnolence, dizziness, muscle spasms, hot flush, cold
sweat and piloerection.
Fig. 1 Study design
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Pharmacokinetics assessments
Venous blood samples for PK analysis were obtained
pre-dose, 15 min, 30 min, 1 h, 1.5 h, 2 h, 3 h, 4 h, 6 h, 8 h,
9 h and 12 h post-dose on dosing days 1 and 10. On dos-
ing day 5, blood PK samples were obtained pre-dose and
at 1 h, 3 h, 6 h and 9 h post-dose. On the remaining days,
only trough samples were taken. Urine for PK analyses
was collected up to 24 h after the first drug administra-
tion and up to 72 h after the last drug administration. In
subjects who were administered 35mg HTL0018318 ac-
cording to the up-titration schedule, extra PK samples
were collected pre-dose on each day and 1, 3, 6 and 9 h
after the 5th administration of 20 mg. Plasma and urine
concentrations of HTL0018318 were determined using
validated bioanalytical methods involving protein pre-
cipitation and liquid chromatography coupled with tan-
dem mass spectrometry. The analytical range of the
assay was 0.5–1000 ng/ml.
PK parameters included in the analysis were the max-
imum observed plasma concentration (Cmax); time to
Cmax (tmax); area under the plasma-concentration-time
curve (AUC) zero to the last measurement (AUClast),
from zero to the end of the dose interval (AUC0-tau) and
from zero to infinity (AUC0-inf); time of the minimum
concentration (tlast); the minimum concentration within
the dosing interval (Cmin); apparent elimination half-life
(t1/2); apparent oral clearance (CL/F); apparent volume
of distribution (Vz/F); renal clearance (CLr); percentage
of dose excreted renally as unchanged drug (Ae%); and
coefficient of variation (%CV). Non-compartmental ana-
lyses were performed on the PK data using Phoenix 64
build 6.4.0.768 using WinNonlin 6.4. Statistical analysis
was performed in R version 3.3.1 (2016-06-21).
Exploratory pharmacodynamic assessments
To assess the acute effects of HTL0018318 on central
nervous system (CNS) functioning, exploratory PD tests
were performed with use of the NeuroCart, a test battery
assessing a wide range of CNS domains, developed to
examine the acute PD effects of CNS-active drugs and
previously shown to be sensitive to cholinergic modula-
tion [23–27]. A customised set of tasks to detect PD ef-
fects to be expected from a cholinergic drug was
performed pre-dose, 1 h, 3 h, 5 h and 9 h post-dose on
dosing days 1, 5 and 10. On dosing day 1, the pre-dose
measurements were performed twice.
The following NeuroCart tests were performed: the
adaptive tracking test measured attention and visuo-
motor coordination; the Milner maze test (MMT) was
used to evaluate spatial working memory, learning and
executive function; the n-back task was used to assess
(short-term) working memory; pupil size was measured
to monitor any drug effects on the sympathetic nervous
system; synaptic/network activity was assessed using
electrophysiology and included resting electroencephalo-
gram (EEG) (power in delta, theta, alpha, beta and
gamma bands) and event-related potentials (ERP) (P300
and Mismatch negativity (MMN)); a visual analogue
scale (VAS) according to Bond and Lader was used to
subjectively assess alertness, mood and calmness; and a
VAS nausea was used to evaluate subjective nausea. The
Leeds Sleep Evaluation Questionnaire (LSEQ) was used
to assess changes in sleep quality. Detailed task descrip-
tions are provided in the supplement methods section.
Saliva production was assessed by measuring the
change in weight of three Salivette® dental rolls put into
the oral cavity for 3 min. Pulmonary function was mea-
sured using the Spirostik (distributed by Accuramed), a
PC-based open spirometry system. Vital signs were also
analysed.
Statistics
No formal hypothesis testing was conducted. The sam-
ple size was chosen based on a compromise between
minimising the exposure of human subjects to a new
chemical entity and the need to provide sufficient data.
Hence, the study was not powered to detect any signifi-
cant treatment effects of small to moderate effect sizes.
The repeatedly measured PD endpoints on dosing days
1, 5 and 10 were analysed with a mixed model analysis
of covariance (ANCOVA) with treatment, time, treat-
ment by time, group, treatment by group, group by time
and treatment by group by time as fixed factors and sub-
ject as random factor and the average baseline measure-
ment as covariate. Least-square means (LSMs) and 95%
confidence intervals (CIs) were estimated from the
ANCOVA models. The repeatedly measured PD param-
eters of the subjects dosed 35mg according to an up-
titration schedule were analysed together with the pla-
cebo subjects of the other elderly cohorts to increase the
power. The data after the up-titration was analysed with
a mixed model ANCOVA with treatment, time and
treatment by time as fixed factors, subject as random
factor and the average baseline measurement before the
up-titration as covariate. All subjects who received at
least one dose of study treatment were included in the
safety and PD analysis set. PD data of the two subjects
who were administered 35mg HTL0018318 not accord-
ing to an up-titration schedule were not analysed. The
following contrasts were calculated for dosing days 1, 5
and 10 separately for every dose level: HTL0018318
(younger adults + elderly subjects) vs placebo (all pla-
cebo subjects pooled together); HTL0018318 (younger
adult subjects) vs placebo (younger adult placebo sub-
jects pooled together); and HTL0018318 (elderly sub-
jects) vs placebo (elderly placebo subjects pooled
together).
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For all outcome parameters, the mean, standard devi-
ation, 95% CI and effect sizes were calculated. All calcu-
lations were performed using SAS for windows V9.4
(SAS Institute, Inc., Cary, NC, USA). MMN data were
excluded from statistical analysis due to limited data
quality and technical issues with stimuli timing and re-
cording. Hence, only resting state EEG power data and
P300 data were reported here.
Results
Subjects
A total of 36 healthy younger adult subjects with a mean
age of 30 years (range 18–53) and with a mean body
mass index (BMI) of 23.7 kg/m2 (range 18–31) were en-
rolled. A total of 50 healthy elderly subjects, with a mean
age of 69.9 years (range 65–83) and with a mean BMI of
25.9 kg/m2 (range 20.5–32.5) were included. See Fig. 2
for subject disposition flow chart. The AEs leading to
withdrawal of six subjects are described below. In one
elderly subject the third dose of 25 mg HTL0018318 was
not administered due to infection-like symptoms and el-
evated c-reactive protein. The subject subsequently re-
covered spontaneously and dosing was resumed.
Safety and tolerability
Multiple doses of 15, 20 and 25 mg HTL0018318 were
generally well-tolerated by healthy younger adult and
elderly subjects. The dose level of 35 mg without up-
titration period was not tolerated by elderly subjects.
The 2 subjects dosed with 35 mg without up-titration
period were withdrawn from the study due to AEs
(hypertension and cold sweat) after the 1st or 2nd ad-
ministration of HTL0018318. Consequently, it was de-
cided to stop dosing 35 mg without an up-titration
period in the remaining subjects of this cohort and to
add an up-titration period preceding the 35 mg doses.
This was relatively well-tolerated with only mild AEs
and no withdrawn subjects. Overall, more subjects dosed
with HTL0018318 reported AEs compared to subjects
dosed with placebo (Tables 1 and 2). In younger adults,
Fig. 2 Subject disposition flow chart
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the number of subjects reporting AEs in general and the
number of cholinergically mediated AEs appeared to be
treatment-related. However, no clear dose-response rela-
tionship was observed. In elderly, the number of subjects
reporting AEs in general and the number of cholinergi-
cally mediated AEs appeared to be treatment- and dose-
related.
The most frequently occurring cholinergically medi-
ated AEs were nausea, hyperhidrosis, chills, cold sweat,
somnolence and feeling cold (see Tables 1 and 2).
In total, 6 subjects were withdrawn from the study be-
cause of AEs. One elderly subject experienced severe
cold sweats and chills after 1 administration of 35 mg
HTL0018318 without up-titration period. One elderly
subject was withdrawn from the study after 2 adminis-
trations of 35 mg HTL0018318 without up-titration
period due to hypertension (supine systolic blood pres-
sure of 168/84 mmHg, increase of > 40% from baseline).
One elderly subject was withdrawn after 1 administra-
tion of 20 mg during the period preceding the 35 mg
dose due to a 40% increase of supine blood pressure to
196/99 mg Hg compared to baseline (140/62 mmHg).
One subject was withdrawn from further participation
after 6 administrations of 25 mg HTL0018318 due to el-
evated liver enzymes AST (76 U/L) and ALT (127 U/L).
The AEs of these 4 subjects were considered to be
related to the study drug. One younger adult subject
was withdrawn after 4 administrations of 25 mg
HTL0018318 because of episodes of bradycardia down to
38 bpm in combination with nausea and fatigue. These ep-
isodes of bradycardia were also observed on the 24-h
Holter monitoring which was part of the screening and
were therefore not considered to be drug-related. One eld-
erly subject was withdrawn because of orthostatic
hypotension 24 h after the first 25mg administration. The
supine blood pressure decreased from 106/48mmHg to
66/37mmHg. As there was no clear relation to peak
plasma HTL0018318 concentration, this AE was not con-
sidered to be related to the study drug.
No consistent clinically relevant abnormalities in
haematology blood results, urinalysis, ECGs and 24-h
Holter monitoring were observed in both younger adult
and elderly subjects. No serious AEs or deaths occurred.
There were no chemistry blood results that showed an
apparent trend toward increased incidence with ascend-
ing dose levels of HTL0018318 during the study.
Pharmacokinetic parameters
The PK parameters and mean concentration-time pro-
files of HTL0018318 are shown in Figs. 3 and 4. These
figures show HTL0018318 arithmetic mean plasma con-
centration against time of 10 daily oral doses of 15, 20











All AEs 5 (55.6) 8 (88.9) 6 (66.7) 6 (66.7) 20 (74.1)
All cholinergic AEs 1 (11.1) 5 (55.6) 5 (55.6) 6 (66.7) 16 (59.3)
Hypertension 0 0 0 0 0
Nausea 0 3 (33.3) 2 (22.2) 4 (44.4) 9 (33.3)
Diarrhoea 0 1 (11.1) 1 (11.1) 0 2 (7.4)
Vomiting 0 0 0 1 (11.1) 1 (3.7)
Hypersalivation 0 0 0 1 (11.1) 1 (3.7)
Hyperhidrosis 0 1 (11.1) 4 (44.4) 3 (33.3) 8 (29.6)
Constipation 0 0 0 0 0
Chills 0 1 (11.1) 0 0 1 (3.7)
Cold sweat 0 0 0 0 0
Feeling cold 0 0 1 (11.1) 0 1 (3.7)
Feeling hot 0 0 1 (11.1) 0 1 (3.7)
Feeling of body temperature change 0 0 0 0 0
Hot flush 0 0 1 (11.1) 2 (22.2) 3 (11.1)
Piloerection 0 0 2 (22.2) 0 2 (7.4)
Peripheral coldness 0 0 0 0 0
Insomnia 1 (11.1) 0 0 0 0
Dizziness 0 0 1 (11.1) 1 (11.1) 2 (7.4)
Muscle spasm 0 1 (11.1) 0 0 1 (3.7)
Data are shown as number (percentage) of subjects reporting AEs
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or 25 mg for younger adult subjects (Fig. 3) and add-
itionally mean (± SD) plasma concentrations of 35 mg in
elderly subjects (Fig. 4). The absorption was rapid with a
median Tmax of 1 h post-dose (range 0.5 to 4 h). The oral
PK profile was biphasic after Cmax. The mean (SD)
apparent terminal half-life in healthy subjects was 16.1 h
(± 4.61) in younger adult subjects and 14.3 h (± 2.78 h)
in elderly subjects determined up to 72 h post-dose. A
mean accumulation index of 1.32 was seen in younger
adult and 1.29 in elderly subjects following the 10th















All AEs 8 (57.1) 7 (77.8) 7 (77.8) 9 (100.0) 2 (100.0) 7 (100.0) 32 (88.9)
All cholinergic AEs 2 (14.3) 1 (11.1) 5 (55.6) 7 (77.8) 2 (100) 7 (100) 22 (61.1)
Hypertension 0 0 0 1 1 1 3 (8.3)
Nausea 0 1 (11.1) 1 (11.1) 2 (22.2) 0 0 4 (11.1)
Diarrhoea 0 0 0 1 (11.1) 0 0 1 (2.8)
Vomiting 0 0 0 0 0 0 0
Constipation 1 (7.1) 0 0 0 0 0 0
Hypersalivation 0 0 0 0 0 0 0
Hyperhidrosis 0 0 3 (33.3) 5 (55.6) 0 2 (28.6) 10 (27.8)
Chills 0 0 0 1 (11.1) 0 4 (57.1) 5 (13.9)
Cold sweat 0 0 0 0 1 (50.0) 2 (28.6) 3 (8.3)
Feeling cold 1 (7.1) 0 1 (11.1) 2 (22.2) 1 (50.0) 2 (28.6) 6 (16.7)
Feeling hot 0 0 0 2 (22.2) 0 0 2 (5.6)
Feeling of body temperature change 0 0 0 1 (11.1) 0 0 1 (2.8)
Hot flush 0 0 2 (22.2) 1 (11.1) 0 2 (28.6) 5 (13.9)
Peripheral coldness 0 0 0 0 1 (50.0) 0 1 (2.8)
Piloerection 0 0 0 0 0 0 0
Insomnia 0 0 1 0 0 0 1 (2.8)
Dizziness 1 0 0 3 0 0 3 (8.3)
Muscle spasm 0 0 1 0 0 0 1 (2.8)
Data are shown as number of subjects reporting adverse events (percentage of subjects)
Fig. 3 HTL0018318 mean plasma concentration after 15, 20 or 25 mg for younger adult subjects
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dose, in terms of AUC0–24. Steady state was reached in
approximately two or three doses. The ratio between the
mean multiple dose AUC0-tau to the AUC0-inf after the
1st dose was 1.06 following the 5th and 1.14 following
the 10th dose in younger adults and 1.03 following the
5th and 1.07 following the 10th dose in elderly subjects.
On average, elderly subjects appeared to have lower oral
clearance than the younger adults (mean (SD) CLss/F
18.3 (± 6.68) L/h in younger adult and 16.0 (± 6.79) L/h
in elderly subjects). The inter-individual variability in
Cmax, AUC and t½ was moderate, with a %CV typically
< 30 and not larger than 66 for any variable.
Exposure to HTL0018318 was dose-proportional over
the range 15 to 35mg. Exposure in elderly subjects given
20mg was higher than expected; however, dose-
exposure proportionality did not deviate from linearity
assessed using the power model [28]. The reason for
higher exposure at 20 mg in elderly subjects could not
be determined.
Renal elimination was a major route of clearance. The
mean percentage recovery of HTL0018318 over the 24-h
dose interval following the 10th dose was 58.1% in youn-
ger adults (range 22.3 to 95.3) and 50.4% in elderly sub-
jects (range 25.8 to 95.7%), which represents the
minimum absolute oral bioavailability. The mean renal
clearance was 8.62–8.84 L/h in younger adults and 6.03–
6.23 L/h in elderly subjects.
Central pharmacodynamic biomarkers
HTL0018318 daily dosing for 10 days showed no con-
sistent effects on EEG/ERP, saliva production, LSEQ,
pupil size or VAS scores compared to placebo (table in
result supplement). Although the study was not powered
to detect small to moderate pro-cognitive effects of
HTL0018318, some significant differences compared to
placebo were observed on a number of cognitive tests
including adaptive tracking (a measure of psychomotor
function and attention), the n-back test (a measure of
working memory) and the Milner Maze Test (a measure
of learning and memory).
Adaptive tracking test
Overall, HTL0018318 had no significant effects on the
adaptive tracking test in young and elderly subjects
across doses and testing days. However, after administra-
tion of 20 mg HTL0018318, the time correctly tracked
was improved by 3.605%-point (95% CI [0.672–6.539],
p = 0.0167) compared with placebo, on dosing day 1 in
the elderly subjects (see Fig. 5, data shown as estimate of
the change from baseline performance.).
N-back test
Overall, an improvement in performance in both
younger adult and elderly subjects on the n-back test
(0-, 1- and 2-back conditions) was observed following
administration of all dose levels of HTL0018318 com-
pared with placebo. The effect on the performance on
the most relevant 2-back working memory “accuracy”
measure is reported here. In all observations, a higher
(number correct-number incorrect)/total was observed
indicating better performance. See supplement results
section for data on the 0-back and 1-back (accuracy and
reaction time) and 2-back (reaction time) conditions.
After administration of 15 mg HTL0018318, the 2-
back accuracy score was 0.076 higher on dosing day 1
(95% CI [0.028–0.125], p = 0.0022) and 0.069 higher on
dosing day 10 (95% CI [0.020–0.118], p = 0.0058)
compared with placebo. Following administration of 20
mg HTL0018318, the 2-back accuracy score was 0.108
higher on dosing day 1 (95% CI [0.059–0.157], p =
Fig. 4 HTL0018318 mean plasma concentration after 15, 20, 25 or 35 mg for elderly subjects
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<.0001), 0.068 higher on dosing day 5 (95% CI [0.019–
0.117], p = 0.0073) and 0.066 higher on dosing day 10
(95% CI [0.016–0.115], p = 0.0095), compared with
placebo. After administration of 25 mg HTL0018318, the
2-back accuracy score was 0.068 higher on dosing day 1
(95% CI [0.020–0.117], p = 0.0063) compared with
placebo. These data were analysed separately for younger
adult and elderly subjects. This is presented in Table 3
and Fig. 6.
Milner maze test
Overall, administration of HTL0018318 in both younger
adult and elderly subjects was associated with a reduc-
tion in total exploratory errors and total moves (on
immediate, reversed and delayed conditions) on the
Milner maze test (MMT). There was an overall signifi-
cant treatment effect of HTL0018318 (including dose
level 15 mg, 20 mg, 25 mg and 35 mg) on the perform-
ance of the MMT immediate and reversed condition
Fig. 5 Effects on adaptive tracking (% correctly tracked) in younger adults (a) and elderly subjects (b)
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(MMT immediate exploratory error; MMT immediate
total moves; MMT reversed exploratory error; MMT re-
versed total moves). The data from exploratory errors
are reported here. See supplement results section for
data on the total moves outcome measure which was
generally consistent with the data on exploratory errors
for immediate and delayed conditions. Overall,
HTL0018318 had no significant or consistent effects on
exploratory errors in the Milner Maze delayed condition
across doses and days in young and elderly subjects.
However, selective effects were observed (see supple-
mentary results).
MMT immediate: exploratory errors
HTL0018318 had some significant and consistent effects
on exploratory errors in the Milner maze test at the 15
mg 20mg, 25 mg and 35mg doses across days, particu-
larly in the elderly subjects. In all observations, a lower
number of errors were observed indicating better
performance.
Administration of 15 mg HTL0018318 was associated
with 3.6 fewer exploratory errors on dosing day 1 (95%
CI [− 7.1 to − 0.2], p = 0.0380), 6.7 fewer exploratory er-
rors on dosing day 5 (95% CI [− 10.1 to − 3.2], p =
0.0002) and 4.8 fewer exploratory errors on dosing day
10 (95% CI [− 8.2 to − 1.3], p = 0.0073), compared with
placebo. Following 20 mg HTL0018318, 3.6 fewer ex-
ploratory errors were observed on dosing day 5 (95% CI
[− 7.1 to − 0.1], p = 0.0460), compared with placebo. No
significant effect was observed after administration of 25
mg HTL0018318 on the number of exploratory errors
compared with placebo. Data were analysed separately
for younger adult and elderly subjects. These are pre-
sented in Table 4 (HTL0018318 compared to placebo,
results expressed in exploratory errors) and Fig. 7.
MMT reversed: exploratory errors
Overall, HTL0018318 had some significant and consist-
ent effects on exploratory errors in the Milner maze test
at the 15 mg 20 mg, 25 mg and 35mg doses across days,
in younger adult and elderly subjects. In all observations,
a lower number of errors were observed indicating bet-
ter performance. Administration of 15 mg HTL0018318
was associated with 1.7 fewer exploratory errors on
dosing day 1 (95% CI [− 2.9 to −0.4], p = 0.0086), com-
pared with placebo. After administration of 20 mg
HTL0018318, 1.4 fewer exploratory errors were observed
on dosing day 1 (95% CI [− 2.7 to −0.2], p = 0.0275),
compared with placebo. Administration of 25 mg
HTL0018318 was associated with 2.1 fewer exploratory
errors on dosing day 1 (95% CI [− 3.3 to −0.9], p =
0.0011) and 1.7 fewer exploratory errors on dosing day
10 (95% CI [− 2.9 to −0.4], p = 0.0119), compared with
placebo. The MMT reversed condition data was ana-
lysed separately for younger adult and elderly subjects.
This is presented in Table 5 (HTL0018318 compared to
placebo, results expressed in exploratory errors) and
Fig. 8.
Table 3 Effects on the accuracy of the 2-back performance compared with placebo
Younger adults Elderly
Parameter Day 1 Day 5 Day 10 Day 1 Day 5 Day 10
15mg HTL0018318
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EEG/ERPs
In general, HTL0018318 had no consistent effects on
EEG power. For several EEG bands, some statistically
significant effects in subjects treated with HTL0018318
compared with placebo were observed; however, these
were not consistent across treatment, electrode position
or days of treatment. Similarly, there was no consistent
effect of HTL0018318 on P300 amplitude or latency, al-
though a significant improvement in P300 amplitude
was noted with the 20mg dose in the elderly on dosing
day 1 (mean difference of 3.670 μV, 95% CI [0.554–
6.786], p = 0.0222).
Other pharmacodynamic biomarkers: blood pressure and
pulse rate
Systolic and diastolic blood pressure was not consist-
ently higher or lower in the subjects treated with
HTL0018318 than in the placebo subjects. However,
Fig. 6 Effects on the 2-back accuracy in younger adults (a) and elderly subjects (b)
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some doses of HTL0018318 did demonstrate statistically
significant differences versus placebo at some time
points. The magnitude and direction of change in blood
pressure following HTL008318 treatment was similar for
younger adult and elderly subjects. The statistically sig-
nificant differences in blood pressure on dosing day 1
were relative increases and on dosing day 5 and 10 were
relative decreases compared to placebo. This pattern was
consistent for supine and standing systolic blood pres-
sure and diastolic blood pressure, but with more signifi-
cant effects being noted on diastolic blood pressure than
on systolic blood pressure.
Mean systolic blood pressure increased up to 8.7
mmHg (95% CI [1.6, 15.8], p = 0.0116, dosing day 1, 25
mg in younger adults) and in mean diastolic blood pres-
sure up to 7.0 mmHg (95% CI [2.4, 11.7], p = 0.0036,
dosing day 1, 15 mg in elderly subjects) (Fig. 9a and b,
results shown as estimate of the change from baseline.).
No evidence of a dose response was observed.
There was a statistically significantly higher pulse
rate for the majority of treatment groups versus pla-
cebo across duration of dosing, particularly in supine
pulse rate and in elderly subjects. The maximum in-
crease in mean supine pulse rate was 10 bpm (95% CI
[4.7–15.3], p = 0.0007, dosing day 5 of 35 mg regimen
by up-titration). Similar results were observed in
standing pulse rate. See supplement results section
for data on systolic and diastolic blood pressure and
pulse rate.
Discussion
We previously reported the safety and tolerability of
HTL0018318 following ascending doses in healthy sub-
jects [21]. In this study, we report the safety and toler-
ability of HTL0018318 following multiple ascending
dosing over 10 days in healthy younger adult and elderly
subjects. We also report exploratory PD effects on bio-
markers of cognitive function. Overall, HTL0018318 was
generally well tolerated at the doses tested and there was
some evidence for pro-cognitive effects, particularly on
tests of short term (working) memory and learning.
Systemic exposure of HTL0018318 showed dose-
proportional increases and reproducible PK in the 15–
35mg dose range. The plasma concentrations of
HTL0018318 reached a maximum typically 1–2 h post-
dose and the apparent half-life was approximately 16 h
in younger adult subjects and 14 h in elderly subjects.
Elimination of unchanged drug in urine was a major
pathway with renal clearance being similar to the age-
adjusted glomerular filtration rate. PK characteristics
were expected based on the results of the SAD study
[21]. Overall, these data suggest that HTL0018318 has a
PK profile consistent with a once daily regimen with no
clear PK differences between healthy younger adult and
elderly subjects.
Multiple doses of HTL0018318 up to 25mg were well-
tolerated and associated with mild and moderate
treatment-related cholinergically mediated AEs (reported
subjectively) in healthy younger adult and elderly
Table 4 Effects of HTL0018318 on the performance of the Milner maze test immediate condition
Younger adults Elderly
Parameter Day 1 Day 5 Day 10 Day 1 Day 5 Day 10
15mg HTL0018318
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subjects. The highest dose level of 35 mg tested in 2 par-
ticipants without an up-titration period was not toler-
ated by elderly subjects; however, this dose was generally
well tolerated with the dose titration regimen. In the
SAD study, the severity of the AEs was lower, although
in the SAD study 3 of the 9 elderly subjects dosed with
35mg had an increase in blood pressure and more cho-
linergically mediated AEs compared with other dose
levels, suggesting a lower tolerability at this high dose.
Clinically relevant hypertension (an increase of > 40%
compared to the baseline measurement or a blood pres-
sure > 180/115 mmHg) occurred in 3 elderly subject fol-
lowing 20mg, 25 mg or 35mg without up-titration,
which is comparable to the 5 (out of 57) elderly subjects
presenting with increased blood pressure in the SAD
study [21]. The observed increases in systolic blood pres-
sure of up to 4.6 mmHg in the elderly and up to 8.7
mmHg in the younger adult subjects in the current
Fig. 7 Effects on the MMT immediate condition performance in younger adult (a) and elderly subjects (b)
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study and increases up to 11.9 mmHg in the SAD study
were both modest increases and showed no dose-
dependency. The mean supine pulse rate was signifi-
cantly higher in the majority of treatment groups in the
current study (up to 9.6 bpm in the elderly and up to
7.5 bpm in the younger adult subjects) and some evi-
dence for dose dependency. However, it should be noted
that there was a reduction in pulse rate post-dose in the
placebo treated participants and therefore the higher
pulse rate in the HTL0018318 groups demonstrated less
of a reduction (relative to placebo) rather than an in-
crease in pulse rate from baseline with HTL0018318
treatment. While the exact mechanisms associated with
the blood pressure and pulse rate changes are not
known, it is possible that this may be related to M1-me-
diated modulation of postganglionic sympathetic neu-
rons that innervate the heart [29]. Additionally, there
appeared to be a decrease of the cholinergic side effects
following repeated dosing of HTL0018318. For example,
the increases in blood pressure seen on dosing day 1 at-
tenuated over time (see Fig. 9), suggesting that there
may be tolerance to the blood pressure increases with
repeat dosing. This phenomenon probably contributes
to the better tolerance of 35 mg HTL0018318 preceded
by the up-titration period compared to 35 mg
HTL0018318 without up-titration period.
Central PD effects were assessed with a range of cog-
nitive tasks probing psychomotor function/attention,
working memory and learning as well as electrophysio-
logical biomarkers including P300, a marker of attention
and working memory updating. In general, there were
no consistent effects on the electrophysiological bio-
markers, although this is likely to have been due to poor
quality of data and contamination of the P300 data due
to a voltage from the trigger pulses leading to high vari-
ability. Furthermore, many data sets had to be partially
or fully removed due to the artefact (or missing data).
This reduced the usable sample considerably reducing
the statistical power of the analysis. Hence, these data
should be interpreted with caution when interpreting
central PD effects measured with EEG/ERP biomarkers
including P300.
HTL0018318 over 10 days of treatment was associated
with improvements in number of cognitive tests includ-
ing adaptive tracking in elderly subjects (a measure of
psychomotor function and sustained attention), the n-
back test in both younger adults and elderly subjects (a
measure of working memory) and the MMT in elderly
subjects (a measure of learning and memory). Overall,
HTL0018318 had more consistent effects across cogni-
tive domains in the elderly compared to younger adults,
although the study was not adequately powered to inves-
tigate differential effects between the two groups. The
magnitude of effects on adaptive tracking (i.e. 3.6%-point
improvement) was comparable to that previously re-
ported with Donepezil (10 mg) in healthy subjects [23]
but were only observed at the 20mg dose and only on
dosing day 1 in elderly subjects suggesting that effects
on psychomotor speed and sustained attention were not
robust and consistently modulated by M1 receptor
Table 5 Effects of HTL0018318 on the performance of the Milner maze test reversed condition
Younger adults Elderly
Parameter Day 1 Day 5 Day 10 Day 1 Day 5 Day 10
15mg HTL0018318
MMTRev: Expl Error −1.9
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modulation with HTL0018318. This is consistent with
the lack of effects we previously reported with the M1
agonist HTL0009936 on adaptive tracking performance .
It is possible that cholinergic and M1 receptor modula-
tion of attentional processing may depend on “atten-
tional effort” or activation of attentional systems by
motivation, particularly in the face of challenges such as
distractors where a high level of attentional control is
needed [30]. In this context, the adaptive tracking task
may have not been challenging enough to require suffi-
cient attentional effort for M1 activation to modulate
performance. The effects on tests of memory (n-back
and MMT) were however more consistent in younger
adult and elderly subjects across doses and over the 10
days of treatment with clinically relevant effects of mod-
erate to large effect sizes. These effects in healthy
Fig. 8 Effects on the MMT reversed condition performance in younger adults (a) and elderly subjects (b)
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normal subjects (presumably with minimal cholinergic
dysfunction) are encouraging and may suggest M1 recep-
tor modulation may have significant effects on learning
and memory in disorders of cholinergic dysfunction such
as AD and other dementias. The n-back test is a working
memory test associated with prefrontal function [31, 32],
while the MMT is a learning and memory test associated
with hippocampal function [33]. Both the prefrontal
cortex and hippocampus are areas rich in muscarinic M1
receptors [13, 34]. The sensitivity of these tests to mus-
carinic (and M1) receptor modulation is supported by
previous studies with the non-selective muscarinic an-
tagonist scopolamine and the M1 antagonist biperiden
which have been shown to impair performance on tests
comparable to the n-back test (45, 46) and MMT (47).
The findings of the current study demonstrating positive
Fig. 9 Effects on systolic blood pressure (a) and pulse rate (b)
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effects of HTL0018318 on tests of short-term memory
and learning are also consistent with the pre-clinical [35,
36] and clinical studies [16, 37] that have similarly
shown improvements tests of learning and memory with
selective M1 receptor agonists. These findings, while pre-
liminary, provide encouraging data in support of the de-
velopment of HTL0018318 for cognitive dysfunction in
AD and other dementias.
The effects of HTL0018318 was also examined on other
PD markers including saliva production, LSEQ, pupil size
or VAS scores, but overall no significant changes were ob-
served (table in result supplement). While our data showed
no effects on saliva production, hypersalivation was ob-
served in other studies investigating other less selective M1
mAChR agonists [16, 38–40] and could be explained by
their relatively small effects on the M3 receptors [40]. The
observation in the current study confirms the selectivity of
HTL0018318 for muscarinic M1 receptors.
Limitations
There are some limitations of the study that warrant dis-
cussion. This study was primarily a safety and tolerability
study and the PD measurements were exploratory. As
such, these data need to be interpreted with caution, given
the small sample size and the lack of power in the study
to detect pro-cognitive effects of small to moderate mag-
nitude. While effect sizes were calculated to nuance the
PD results calculated by the statistic model (table in result
supplement), it is possible that the small sample size could
over- or underestimate the pro-cognitive effects of
HTL0018318. As discussed above, the EEG/ERP were of
poor data quality driven by a voltage noise from the trig-
ger pulses leading to high variability and significant loss of
data. Hence, no definite conclusions can be made with re-
gard to the absence of effects of HTL0018318 on the EEG
and ERP biomarkers of cognitive function.
Conclusions
In conclusion, HTL0018318 was generally well-tolerated
in multiple doses up to 25mg/day and dosed up to 10
days (in adult and elderly subjects) or up to 15 days ac-
cording to a titration regimen of 20 mg/day for 5 days
followed by 35 mg/day for 10 days in elderly subjects.
The multiple dose PK of HTL0018318 were well-
characterised. Treatment-related AEs including choliner-
gically mediated AEs were mild and transient. Modest
changes in blood pressure were observed after the first
dose administration, which returned to normal after
multiple doses. Consistent and pro-cognitive effects of
moderate to large magnitude on short-term memory
and learning were demonstrated across the dose range
over the 10 days of treatment providing encouraging
data in support of the development of HTL0018318 for
cognitive dysfunction in dementias.
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